This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Wed, 05/15/2024 - 19:05 May 15, 2024 — CardioFocus, Inc. , a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the Heart Rhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024.
PFA on Display As you walked into the expo hall, it was hard to miss the large space-age light displays of the Farapulse Pulsed Field Ablation system from Boston Scientific and the PulseSelect PFA system from Medtronic. Pulsed field ablation (PFA) is all the rage in electrophysiology. So, again, innovation is great.
Pulsed field ablation (PFA) is an emerging non-thermal technique that is gaining traction due to the ability to selectively target myocardial cells and minimize damage to surrounding tissues. The number of publications increased rapidly from 2019 to 2024, with a notable surge occurring after 2022.
Radiofrequency ablation (RFA) is an important therapeutic modality for atrial fibrillation (AF), widely utilized in clinical practice due to its safety and significant efficacy. This case report describes a unique instance of a patient developing AEF following AF ablation, accompanied by ischemic stroke and myocardial infarction.
milla1cf Mon, 01/08/2024 - 14:26 January 8, 2024 — Stereotaxis , a pioneer in surgical robotics for minimally invasive endovascular intervention, announced that the first patients have been successfully treated using its Magnetic Interventional Ablation Catheter, MAGiC. Physicians at Vilnius University.
Food and Drug Administration (FDA), has granted approval to Boston Scientific for its FARAPULSE Pulsed Field Ablation System. intermittent) atrial fibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment. said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific.
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. Early recurrence of atrial tachyarrhythmia (ERAT) is commonly seen following catheter ablation of AF, with reported incidences of up to 61% in the first three months.
milla1cf Mon, 01/29/2024 - 11:00 January 29, 2024 — The Society of Thoracic Surgeons has released late-breaking research scheduled for presentation at the 2024 Annual Meeting taking place January 27 - 29 in San Antonio.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S. Circulation.
milla1cf Fri, 02/02/2024 - 17:02 February 2, 2024 — Biosense Webster, Inc. , Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium.
Getty Images milla1cf Tue, 02/06/2024 - 20:36 February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial ( NCT05883631 ), a study formally launched in late October 2023. By guiding ablation therapy, [EGF mapping] can enable clinicians to provide personalized, highly targeted treatment."
milla1cf Thu, 01/18/2024 - 14:21 January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib).
The first half of 2024 is now a wrap, and it was another big one in cardiology. Pulsed Field Awakening – Pulsed field ablation was the clear electrophysiology highlight of 2024 so far, after dominating conversations at HRS 2024 , producing mounting evidence of its advantages, and scoring its first FDA approval.
The AFib pulsed field ablation treatment era officially began in the US last week, following the FDA approval of Medtronic’s PulseSelect Pulsed Field Ablation System for the treatment of both paroxysmal and persistent atrial fibrillation. The PulseSelect gained CE Mark approval in November, and will launch commercially in early 2024.
We hope everyone who attended HRS 2024 had a blast, and we hope all of you enjoy these top-six takeaways from electrophysiology’s biggest weekend of the year. The post Cardiac Wire’s Top Six Takeaways from HRS 2024 appeared first on Cardiac Wire.
Pulsed field ablation (PFA) has emerged as a safe and effective alternative to thermal ablation modalities. Its tissue selectiveness stands out as a most important advantage over radiofrequency (RF) ablation or cryoablation, along with a shorter ablation time.
FDA approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation and FDA 510(k) clearance for the new FARAVIEW Software, which will combine to provide visualization for cardiac ablation procedures with the FARAPULSE Pulsed Field Ablation System.
David passed away suddenly on February 10, 2024. David’s many scholarly contributions focused on ablation energy sources, starting in 1986 when he was at the University of Virginia (UVA) and radiofrequency ablation was being introduced.
ISC 2024 Late-breaking Science Finding from ZODIAC Study: Position of Head Before Surgery May Improve Stroke Patient’s Neurological Function 3. ISC 2024 News: Late-Breaking Science Findings from EMBOLISE Clinical Trial Reveals Blocking Artery Supplying the Brain Covering After Subdural Hematoma Reduced Repeat Surgery 4.
Left atrial appendage closure (LAAC) in patients at moderate to high risk for stroke who were undergoing catheter atrial fibrillation (AFib) ablation resulted in significantly less bleeding compared with oral anticoagulation, based on findings from the OPTION trial presented at AHA 2024 and simultaneously published in NEJM.
Pulsed field ablation (PFA) was approved by the FDA in 2024 for use in patients undergoing catheter ablation of atrial fibrillation (AF). To date, there are few comparative data between the two commercially available systems in the United States.
BackgroundCryoablation for pediatric atrioventricular nodal reentry tachycardia (AVNRT) is favored for reducing conduction system injury compared to radiofrequency (RF) ablation. The safety advantage of cryoablation over RF ablation primarily results from studies conducted without a three-dimensional electroanatomical mapping (3D EAM) system.
milla1cf Wed, 06/19/2024 - 20:57 June 19, 2024 — When electrophysiologist Eugenio Cingolani, MD , isn’t seeing patients, he can usually be found in his laboratory, investigating improved treatments for heart rhythm disorders. Unfortunately, ablation also destroys healthy heart tissue in the process. Eugenio Cingolani, MD.
However, its predictive efficacy for AF recurrence remains controversial.MethodsWe searched PubMed and Google databases for studies before January 2024 evaluating the association between QTc interval and AF incidence.
We appreciate the immense effort undertaken by the writing committee to produce the outstanding 2024 Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation (AF)(1). A notable omission exists in section 7.4:
Pulsed Field Ablation is a relatively new modality for treatment of atrial fibrillation. In conventional ablation for atrial fibrillation, either heating of tissue is produced by radiofrequency application or freezing of tissues by cryoablation. Pulsed field ablation group had 305 patients while thermal ablation group had 302 patients.
Pulsed-field ablation (PFA) of the pulmonary veins (PVs) can have an impact on the neighboring structures, such as the superior vena cava (SVC) (Ogawa T et al. The presence of metallic electrodes distorts the electric field distribution in the ablation lesion and may affect the lesion formation in the neighboring structures during PFA.
Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment 8. Weight Loss Drug Linked with Reduced Need for Diuretics in Heart Failure Patients 7. Geisinger Enrolls First Patient in Amyloid Cardiomyopathy Trial 9.
milla1cf Tue, 03/12/2024 - 16:44 March 12, 2024 — Stereotaxis , a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced that regulatory submissions were made recently in both Europe and the United States for the MAGiC catheter. Physicians at Vilnius University Hospital.
milla1cf Thu, 05/30/2024 - 10:31 May 30, 2024 — Stereotaxis , a pioneer in surgical robotics for minimally invasive endovascular intervention, announced the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System.
Pulsed-field energy ablation (PFA) was significantly associated with hemolysis compared to radiofrequency ablation (RFA) following pulmonary vein isolation (PVI), according to the results of a study presented at Heart Rhythm 2024.
Simultaneously, thanks to the revolutionary work of cardiac electrophysiology (EP) physicians, scientists, and industry, ablative treatment of complex arrhythmias including AF has achieved ever-increasing efficacy and safety.
milla1cf Tue, 06/11/2024 - 18:09 June 11, 2024 — Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac heart program in Southern Italy.
International Stroke Conference 2024 to Present High-Profile Late-Breaking Science 6. Abbott Announces First Global Procedures in a Clinical Trial of its Volt Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms A Dietary Supplement Leads to Remarkable Regression in Atherosclerotic Lesions 2.
a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.
A catheter ablation procedure widely used to treat the most common heart rhythm disorder significantly reduces the burden of atrial fibrillation (AF) and results in clinically important improvements in symptoms and quality of life compared with a sham (placebo) procedure, according to late breaking research presented Sept.
This study of 16 patients with persistent left superior vena cava (PLSVC) undergoing atrial fibrillation ablation shows a 66.7% identification rate of PLSVC-related triggers and an 85% success rate in acute isolation or targeted ablation. However, a 46.7% The primary endpoints were procedural safety and AF recurrence postablation.
mtaschetta-millane Wed, 07/17/2024 - 11:06 July 17, 2024 — BioCardia, Inc. , This additional patent protection for BioCardia’s current and future products in this important existing market enhances shareholder value.
Atrioventricular nodal (AVN) ablation with permanent pacemaker implantation – ‘pace and ablate’ – may be considered for patients with symptomatic atrial fibrillation (AF) for whom rhythm control has been unsuccessful. Conduction-system pacing mitigates PICM, so we expect a greater uptake of AVN ablation going forward.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content